Spontaneous object recognition and its relevance to schizophrenia: a review of findings from pharmacological, genetic, lesion and developmental rodent models
暂无分享,去创建一个
L. Saksida | T. Bussey | L. Lyon | L. M. Saksida | T. J. Bussey | L. Lyon
[1] Yuko Fujita,et al. Phencyclidine-Induced Cognitive Deficits in Mice Are Improved by Subsequent Subchronic Administration of the Novel Selective α7 Nicotinic Receptor Agonist SSR180711 , 2008, Biological Psychiatry.
[2] Serologic evidence of prenatal influenza in the etiology of schizophrenia , 2004 .
[3] H. Lublin,et al. Effects of Donepezil Adjunctive Treatment to Ziprasidone on Cognitive Deficits in Schizophrenia: A Double-blind, Placebo-Controlled Study , 2007, Clinical neuropharmacology.
[4] T. Bussey,et al. Hippocampal lesions that abolish spatial maze performance spare object recognition memory at delays of up to 48 hours , 2005, Hippocampus.
[5] Sven Andréasson,et al. CANNABIS AND SCHIZOPHRENIA A Longitudinal Study of Swedish Conscripts , 1987, The Lancet.
[6] N. Pitsikas,et al. The nitric oxide-releasing derivative of ferulic acid NCX 2057 antagonized delay-dependent and scopolamine-induced performance deficits in a recognition memory task in the rat , 2010, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[7] J. Sweeney,et al. Drug abuse in schizophrenic patients: clinical correlates and reasons for use. , 1991, The American journal of psychiatry.
[8] G. Nomikos,et al. Effects of Typical and Atypical Antipsychotics and Receptor Selective Compounds on Acetylcholine Efflux in the Hippocampus of the Rat , 2002, Neuropsychopharmacology.
[9] T. Comery,et al. Procognitive and Neuroprotective Activity of a Novel α7 Nicotinic Acetylcholine Receptor Agonist for Treatment of Neurodegenerative and Cognitive Disorders , 2009, Journal of Pharmacology and Experimental Therapeutics.
[10] G. Robertson,et al. Darbepoetin alfa (Aranesp®) improves recognition memory in adult rats that have sustained bilateral ventral hippocampal lesions as neonates or young adults , 2007, Neuroscience.
[11] E. Godaux,et al. GSK3ß, a centre-staged kinase in neuropsychiatric disorders, modulates long term memory by inhibitory phosphorylation at Serine-9 , 2009, Neurobiology of Disease.
[12] G. Reynolds,et al. Effect of pretreatment with risperidone on phencyclidine-induced disruptions in object recognition memory and prefrontal cortex parvalbumin immunoreactivity in the rat , 2010, Behavioural Brain Research.
[13] M. Day,et al. Correlating Efficacy in Rodent Cognition Models with in Vivo 5-Hydroxytryptamine1A Receptor Occupancy by a Novel Antagonist, (R)-N-(2-Methyl-(4-indolyl-1-piperazinyl)ethyl)-N-(2-pyridinyl)-cyclohexane Carboxamide (WAY-101405) , 2008, Journal of Pharmacology and Experimental Therapeutics.
[14] P. Seeman,et al. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. , 1975, Science.
[15] Hughes,et al. Correlating Efficacy in Rodent Cognition Models with In Vivo 5-HT 1 A Receptor Occupancy by a Novel Antagonist , 2008 .
[16] A. Sleight,et al. Reversal of a cholinergic-induced deficit in a rodent model of recognition memory by the selective 5-HT6 receptor antagonist, Ro 04-6790 , 2003, Psychopharmacology.
[17] S. Katayama,et al. Subsequent exposure to the choline uptake enhancer MKC-231 antagonizes phencyclidine-induced behavioral deficits and reduction in septal cholinergic neurons in rats , 2007, European Neuropsychopharmacology.
[18] Karl J. Friston,et al. The left medial temporal region and schizophrenia. A PET study. , 1992, Brain : a journal of neurology.
[19] L. Rothblat,et al. Short-term object recognition memory in the rat: nonmatching with trial-unique junk stimuli. , 1987, Behavioral neuroscience.
[20] J. Vry,et al. The Novel α7 Nicotinic Acetylcholine Receptor Agonist N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide Improves Working and Recognition Memory in Rodents , 2007, Journal of Pharmacology and Experimental Therapeutics.
[21] E. Levin,et al. Nicotinic-antipsychotic drug interactions and cognitive function. , 2006, EXS.
[22] J C Gordon,et al. The 5-HT3 antagonist tropisetron (ICS 205-930) is a potent and selective alpha7 nicotinic receptor partial agonist. , 2001, Bioorganic & medicinal chemistry letters.
[23] R. Ebstein,et al. Dopamine D4 receptor (D4DR) exon III polymorphism associated with the human personality trait of Novelty Seeking , 1996, Nature Genetics.
[24] Herbert Y Meltzer,et al. Efficacy and Safety of Donepezil in Patients with Schizophrenia or Schizoaffective Disorder: Significant Placebo/Practice Effects in a 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial , 2008, Neuropsychopharmacology.
[25] Robert E. Clark,et al. Impaired Recognition Memory in Rats after Damage to the Hippocampus , 2000, The Journal of Neuroscience.
[26] Kevin B Baker,et al. Effects of stress and hippocampal NMDA receptor antagonism on recognition memory in rats. , 2002, Learning & memory.
[27] F. Lung,et al. Association of DRD4 uVNTR and TP53 codon 72 polymorphisms with schizophrenia: a case-control study , 2009, BMC Medical Genetics.
[28] C. Messier. Object Recognition in Mice: Improvement of Memory by Glucose , 1997, Neurobiology of Learning and Memory.
[29] R. Freedman,et al. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. , 2006, Archives of general psychiatry.
[30] R. Gainetdinov,et al. The Physiology, Signaling, and Pharmacology of Dopamine Receptors , 2011, Pharmacological Reviews.
[31] J. Waddington,et al. Chronic Adolescent Exposure to Δ-9-Tetrahydrocannabinol in COMT Mutant Mice: Impact on Psychosis-Related and Other Phenotypes , 2010, Neuropsychopharmacology.
[32] N. Alpert,et al. Abnormalities in the thalamus and prefrontal cortex during episodic object recognition in schizophrenia , 2000, Biological Psychiatry.
[33] J. Glennon,et al. SLV313 (1-(2,3-Dihydro-Benzo[1,4]Dioxin-5-yl)-4- [5-(4-Fluoro-Phenyl)-Pyridin-3-ylmethyl]-Piperazine Monohydrochloride): A Novel Dopamine D2 Receptor Antagonist and 5-HT1A Receptor Agonist Potential Antipsychotic Drug , 2007, Neuropsychopharmacology.
[34] H. Meltzer,et al. Effect of muscarinic receptor agonists xanomeline and sabcomeline on acetylcholine and dopamine efflux in the rat brain; comparison with effects of 4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one (AC260584) and N-desmethylclozapine. , 2008, European journal of pharmacology.
[35] A. E. A. Yağcıoğlu,et al. A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia. , 2004, The international journal of neuropsychopharmacology.
[36] Rosemary A. Cowell,et al. Perceptual Functions of Perirhinal Cortex in Rats: Zero-Delay Object Recognition and Simultaneous Oddity Discriminations , 2007, The Journal of Neuroscience.
[37] S. Totterdell,et al. Enhanced anxiety, depressive‐like behaviour and impaired recognition memory in mice with reduced expression of the vesicular glutamate transporter 1 (VGLUT1) , 2007, The European journal of neuroscience.
[38] R. Schreiber,et al. The Selective 5-HT6 Receptor Antagonist Ro4368554 Restores Memory Performance in Cholinergic and Serotonergic Models of Memory Deficiency in the Rat , 2005, Neuropsychopharmacology.
[39] Jared W. Young,et al. Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. , 2009, Pharmacology & therapeutics.
[40] L. Saksida,et al. New translational assays for preclinical modelling of cognition in schizophrenia: The touchscreen testing method for mice and rats , 2012, Neuropharmacology.
[41] Yuko Fujita,et al. Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent subchronic administration of donepezil: Role of sigma-1 receptors , 2009, Brain Research.
[42] Keith A. Young,et al. Galantamine Improves Cognition in Schizophrenic Patients Stabilized on Risperidone , 2006, Biological Psychiatry.
[43] B. Bogerts,et al. Cellular changes in rat brain areas associated with neonatal hippocampal damage. , 1999, Neuroreport.
[44] L R Squire,et al. On the development of declarative memory. , 1993, Journal of experimental psychology. Learning, memory, and cognition.
[45] Yuko Fujita,et al. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[46] F. Liu,et al. ADX47273 [S-(4-Fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: A Novel Metabotropic Glutamate Receptor 5-Selective Positive Allosteric Modulator with Preclinical Antipsychotic-Like and Procognitive Activities , 2008, Journal of Pharmacology and Experimental Therapeutics.
[47] Michael F. Green,et al. Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. , 2006, The Journal of clinical psychiatry.
[48] R. Freedman,et al. Effects of Nicotine on Cognitive Deficits in Schizophrenia , 2004, Neuropsychopharmacology.
[49] W. Montfort,et al. The nitric oxide-releasing heme proteins from the saliva of the blood-sucking insect Rhodnius prolixus , 2000 .
[50] E. Wong,et al. Asenapine Increases Dopamine, Norepinephrine, and Acetylcholine Efflux in the Rat Medial Prefrontal Cortex and Hippocampus , 2008, Neuropsychopharmacology.
[51] Michael F. Green,et al. Methamphetamine dependence is associated with neurocognitive impairment in the initial phases of abstinence. , 2003, The Journal of neuropsychiatry and clinical neurosciences.
[52] R. Papke,et al. TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia. , 2009, Biochemical pharmacology.
[53] L. Dawson,et al. Effects of 5-HT6 receptor blockade on the neurochemical outcome of antidepressant treatment in the frontal cortex of the rat , 2003, Journal of Neural Transmission.
[54] Joseph P. Huston,et al. The pharmacology, neuroanatomy and neurogenetics of one-trial object recognition in rodents , 2007, Neuroscience & Biobehavioral Reviews.
[55] Bita Moghaddam,et al. NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[56] J. Crabbe,et al. Genetics of mouse behavior: interactions with laboratory environment. , 1999, Science.
[57] W. Scoville,et al. LOSS OF RECENT MEMORY AFTER BILATERAL HIPPOCAMPAL LESIONS , 1957, Journal of neurology, neurosurgery, and psychiatry.
[58] D. Rasmusson. The role of acetylcholine in cortical synaptic plasticity , 2000, Behavioural Brain Research.
[59] J. Neill,et al. Activation of α7 nicotinic receptors improves phencyclidine-induced deficits in cognitive tasks in rats: Implications for therapy of cognitive dysfunction in schizophrenia , 2011, European Neuropsychopharmacology.
[60] Alan S. Brown,et al. Prenatal infection as a risk factor for schizophrenia. , 2006, Schizophrenia bulletin.
[61] Thomas J. Raub,et al. Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationship. , 2006, Journal of medicinal chemistry.
[62] A. Sawa,et al. Combined effect of neonatal immune activation and mutant DISC1 on phenotypic changes in adulthood , 2010, Behavioural Brain Research.
[63] A. Carlsson,et al. EFFECT OF CHLORPROMAZINE OR HALOPERIDOL ON FORMATION OF 3METHOXYTYRAMINE AND NORMETANEPHRINE IN MOUSE BRAIN. , 2009, Acta pharmacologica et toxicologica.
[64] T. Robbins. Synthesizing schizophrenia: a bottom-up, symptomatic approach. , 2005, Schizophrenia bulletin.
[65] O. Pascalis,et al. Visual paired comparison performance is impaired in a patient with selective hippocampal lesions and relatively intact item recognition , 2004, Neuropsychologia.
[66] T. Bussey,et al. Functionally Dissociating Aspects of Event Memory: the Effects of Combined Perirhinal and Postrhinal Cortex Lesions on Object and Place Memory in the Rat , 1999, The Journal of Neuroscience.
[67] T. Comery,et al. 5-Cyclic amine-3-arylsulfonylindazoles as novel 5-HT6 receptor antagonists. , 2010, Journal of Medicinal Chemistry.
[68] R. Roesler,et al. Pre- or post-training administration of the NMDA receptor blocker MK-801 impairs object recognition memory in rats , 2005, Behavioural Brain Research.
[69] R. Quirion,et al. Local modulation of hippocampal acetylcholine release by dopamine D1 receptors: a combined receptor autoradiography and in vivo dialysis study , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[70] James M Gold,et al. Galantamine for the treatment of cognitive impairments in people with schizophrenia. , 2008, The American journal of psychiatry.
[71] D. Weinberger,et al. Genetic Dissection of the Role of Catechol-O-Methyltransferase in Cognition and Stress Reactivity in Mice , 2008, The Journal of Neuroscience.
[72] A. Malhotra,et al. Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. , 1999, The American journal of psychiatry.
[73] Sarah L. Huszar,et al. The Behavioral and Neurochemical Effects of a Novel d-Amino Acid Oxidase Inhibitor Compound 8 [4H-Thieno [3,2-b]pyrrole-5-carboxylic Acid] and d-Serine , 2008, Journal of Pharmacology and Experimental Therapeutics.
[74] V. R. Marcy,et al. Activation of the 5-HT6 receptor attenuates long-term potentiation and facilitates GABAergic neurotransmission in rat hippocampus , 2009, Neuroscience.
[75] Rosemary A. Cowell,et al. Why Does Brain Damage Impair Memory? A Connectionist Model of Object Recognition Memory in Perirhinal Cortex , 2006, The Journal of Neuroscience.
[76] A. Yonelinas,et al. Recollection and familiarity: Examining controversial assumptions and new directions , 2010, Hippocampus.
[77] S. Lal,et al. Nicotine and Behavioral Markers of Risk for Schizophrenia: A Double-Blind, Placebo-Controlled, Cross-Over Study , 2002, Neuropsychopharmacology.
[78] L. Dawson,et al. The 5-HT6 Receptor Antagonist SB-271046 Selectively Enhances Excitatory Neurotransmission in the Rat Frontal Cortex and Hippocampus , 2001, Neuropsychopharmacology.
[79] J. Neumaier,et al. 5-HT6 receptors: a novel target for cognitive enhancement. , 2005, Pharmacology & therapeutics.
[80] T. Rodrigo,et al. Memantine is a useful drug to prevent the spatial and non-spatial memory deficits induced by methamphetamine in rats. , 2010, Pharmacological research.
[81] P. Goldman-Rakic. Working memory dysfunction in schizophrenia. , 1994, The Journal of neuropsychiatry and clinical neurosciences.
[82] Sophia Vinogradov,et al. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. , 2004, The American journal of psychiatry.
[83] P. Allebeck,et al. CANNABIS AND SCHIZOPHRENIA , 1988, The Lancet.
[84] E. Wood,et al. Nonrecurring-items delayed nonmatching-to-sample in rats: A new paradigm for testing nonspatial working memory , 1990, Psychobiology.
[85] T. Wienker,et al. Splitting schizophrenia: periodic catatonia-susceptibility locus on chromosome 15q15. , 2000, American journal of human genetics.
[86] H. Meltzer,et al. Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism , 2002, Brain Research.
[87] T. Abel,et al. Neuregulin 1 transgenic mice display reduced mismatch negativity, contextual fear conditioning and social interactions , 2009, Brain Research.
[88] Z. Bashir,et al. A temporally distinct role for group I and group II metabotropic glutamate receptors in object recognition memory. , 2006, Learning & memory.
[89] T. Svensson,et al. Asenapine elevates cortical dopamine, noradrenaline and serotonin release. Evidence for activation of cortical and subcortical dopamine systems by different mechanisms , 2009, Psychopharmacology.
[90] J. Haller,et al. WIN-55,212-2 chronically implanted into the CA3 region of the dorsal hippocampus impairs learning: a novel method for studying chronic, brain-area-specific effects of cannabinoids , 2007, Behavioural pharmacology.
[91] Robert Freedman,et al. Proof-of-Concept Trial of an α7 Nicotinic Agonist in Schizophrenia , 2006 .
[92] John P. Aggleton,et al. Interleaving brain systems for episodic and recognition memory , 2006, Trends in Cognitive Sciences.
[93] P. Patterson,et al. Maternal immune activation alters nonspatial information processing in the hippocampus of the adult offspring , 2010, Brain, Behavior, and Immunity.
[94] M. W. Brown,et al. Evidence concerning how neurons of the perirhinal cortex may effect familiarity discrimination. , 2002, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[95] Boyer D. Winters,et al. Object recognition memory: Neurobiological mechanisms of encoding, consolidation and retrieval , 2008, Neuroscience & Biobehavioral Reviews.
[96] L. Dawson,et al. In vivo effects of the 5‐HT6 antagonist SB‐271046 on striatal and frontal cortex extracellular concentrations of noradrenaline, dopamine, 5‐HT, glutamate and aspartate , 2000, British journal of pharmacology.
[97] C L DeVane,et al. A Double-blind Placebo-controlled Case Study of the Use of Donepezil to Improve Cognition in a Schizoaffective Disorder Patient: Functional MRI Correlates. , 2001, Neurocase.
[98] A. Phillips,et al. Medial prefrontal cortex is involved in spatial temporal order memory but not spatial recognition memory in tests relying on spontaneous exploration in rats , 2004, Behavioural Brain Research.
[99] L. Dawson,et al. The 5-HT(6) receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus. , 2001, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.
[100] Raquel E Gur,et al. Face recognition memory deficits and visual object memory performance in patients with schizophrenia and their relatives. , 2005, The American journal of psychiatry.
[101] D. Suchecki,et al. Pituitary-adrenal and interleukin-6 responses to recombinant interleukin-1 in neonatal rats , 1994, Psychoneuroendocrinology.
[102] S. Lal,et al. Cognitive and clinical moderators of recognition memory in schizophrenia: a meta-analysis , 2005, Schizophrenia Research.
[103] Jill Harkavy-Friedman,et al. Resting neural activity distinguishes subgroups of schizophrenia patients , 2004, Biological Psychiatry.
[104] S. Bate,et al. Selective dopamine D4 receptor agonist (A-412997) improves cognitive performance and stimulates motor activity without influencing reward-related behaviour in rat , 2008, Behavioural pharmacology.
[105] T. Bussey,et al. Distinct patterns of behavioural impairments resulting from fornix transection or neurotoxic lesions of the perirhinal and postrhinal cortices in the rat , 2000, Behavioural Brain Research.
[106] Ralph Lydic,et al. Adenosine A1 and A2A Receptors in Mouse Prefrontal Cortex Modulate Acetylcholine Release and Behavioral Arousal , 2009, The Journal of Neuroscience.
[107] Gary Remington,et al. Dopamine D2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient , 2001, Biological Psychiatry.
[108] Malcolm W. Brown,et al. Cholinergic Neurotransmission Is Essential for Perirhinal Cortical Plasticity and Recognition Memory , 2003, Neuron.
[109] P. Celada,et al. Involvement of 5-HT1A Receptors in Prefrontal Cortex in the Modulation of Dopaminergic Activity: Role in Atypical Antipsychotic Action , 2005, The Journal of Neuroscience.
[110] Pedro Grandes,et al. Dopaminergic Modulation of Endocannabinoid-Mediated Plasticity at GABAergic Synapses in the Prefrontal Cortex , 2010, The Journal of Neuroscience.
[111] G. Griebel,et al. SSR180711, a Novel Selective α7 Nicotinic Receptor Partial Agonist: (II) Efficacy in Experimental Models Predictive of Activity Against Cognitive Symptoms of Schizophrenia , 2007, Neuropsychopharmacology.
[112] T. Nabeshima,et al. Repeated methamphetamine treatment impairs spatial working memory in rats: reversal by clozapine but not haloperidol , 2007, Psychopharmacology.
[113] P. Allebeck,et al. Signs of asphyxia at birth and risk of schizophrenia , 2001, British Journal of Psychiatry.
[114] J. Lieberman,et al. A Randomized, Placebo-Controlled Study of Memantine as Adjunctive Treatment in Patients with Schizophrenia , 2009, Neuropsychopharmacology.
[115] E. Levin,et al. Nicotinic acetylcholine involvement in cognitive function in animals , 1998, Psychopharmacology.
[116] Michael Koch,et al. Chronic Pubertal, but not Adult Chronic Cannabinoid Treatment Impairs Sensorimotor Gating, Recognition Memory, and the Performance in a Progressive Ratio Task in Adult Rats , 2003, Neuropsychopharmacology.
[117] D. Greenblatt,et al. Withdrawal reaction from long-term, low-dosage administration of diazepam. A double-blind, placebo-controlled case study. , 1980, Archives of general psychiatry.
[118] M. Miguéns,et al. Chronic periadolescent cannabinoid treatment enhances adult hippocampal PSA-NCAM expression in male Wistar rats but only has marginal effects on anxiety, learning and memory , 2009, Pharmacology Biochemistry and Behavior.
[119] Martín Cammarota,et al. Posttraining activation of CB1 cannabinoid receptors in the CA1 region of the dorsal hippocampus impairs object recognition long-term memory , 2008, Neurobiology of Learning and Memory.
[120] David R. Thomas,et al. Role of 5-HT receptor mechanisms in sub-chronic PCP-induced reversal learning deficits in the rat , 2009, Psychopharmacology.
[121] M. Tsuang,et al. Brief Research Communication Linkage Disequilibrium for Schizophrenia at the Chromosome 15q13-14 Locus of the a7-Nicotinic Acetylcholine Receptor Subunit Gene (CHRNA7) , 2001 .
[122] J. Aggleton,et al. Neurotoxic lesions of the perirhinal cortex do not mimic the behavioural effects of fornix transection in the rat , 1996, Behavioural Brain Research.
[123] D. Bertrand,et al. RG3487, a Novel Nicotinic α7 Receptor Partial Agonist, Improves Cognition and Sensorimotor Gating in Rodents , 2011, Journal of Pharmacology and Experimental Therapeutics.
[124] Maryam Noroozian,et al. A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[125] D. Goff,et al. Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial , 2005, Psychopharmacology.
[126] M. W. Brown,et al. Recognition memory: neuronal substrates of the judgement of prior occurrence , 1998, Progress in Neurobiology.
[127] M. Egan,et al. Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[128] H. Eichenbaum,et al. Serine racemase deletion disrupts memory for order and alters cortical dendritic morphology , 2011, Genes, brain, and behavior.
[129] E. Bromley. A collaborative approach to targeted treatment development for schizophrenia: a qualitative evaluation of the NIMH-MATRICS project. , 2005, Schizophrenia bulletin.
[130] J. Frahm,et al. Complexin2 null mutation requires a ‘second hit’ for induction of phenotypic changes relevant to schizophrenia , 2010, Genes, brain, and behavior.
[131] T. Nabeshima,et al. Repeated Methamphetamine Treatment Impairs Recognition Memory Through a Failure of Novelty-Induced ERK1/2 Activation in the Prefrontal Cortex of Mice , 2006, Biological Psychiatry.
[132] G. Reynolds,et al. A selective reduction in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia patients. , 2002, Chinese medical journal.
[133] Matthew P. Schroeder,et al. Nicotine enhances but does not normalize visual sustained attention and the associated brain network in schizophrenia. , 2011, Schizophrenia bulletin.
[134] Z. Bashir,et al. Activation of muscarinic receptors induces protein synthesis‐dependent long‐lasting depression in the perirhinal cortex , 2001, The European journal of neuroscience.
[135] T. Woo,et al. Schizophrenia and the parvalbumin-containing class of cortical local circuit neurons. , 1997, The American journal of psychiatry.
[136] A. Sahgal,et al. The role of serotonergic-cholinergic interactions in the mediation of cognitive behaviour , 1995, Behavioural Brain Research.
[137] Yuko Fujita,et al. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol. , 2005, European journal of pharmacology.
[138] B. Moghaddam,et al. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. , 1998, Science.
[139] D. Lewis,et al. Cortical inhibitory neurons and schizophrenia , 2005, Nature Reviews Neuroscience.
[140] R. Schreiber,et al. Effects of the novel 5-HT 6 receptor antagonist RO4368554 in rat models for cognition and , 2007 .
[141] J. Schneider,et al. The dopamine D3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures. , 2010, The international journal of neuropsychopharmacology.
[142] T. Karl,et al. Cognition in transmembrane domain neuregulin 1 mutant mice , 2010, Neuroscience.
[143] Mary Johnson,et al. Laminar distribution of nicotinic receptor subtypes in cortical regions in schizophrenia , 2001, Journal of Chemical Neuroanatomy.
[144] P. Coyle,et al. Maternal dietary zinc supplementation prevents aberrant behaviour in an object recognition task in mice offspring exposed to LPS in early pregnancy , 2009, Behavioural Brain Research.
[145] K. Davis,et al. Dopamine in schizophrenia: a review and reconceptualization. , 1991, The American journal of psychiatry.
[146] Sylvain Williams,et al. Behavioral characterization of dysbindin-1 deficient sandy mice , 2009, Behavioural Brain Research.
[147] Peter B. Jones,et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review , 2007, The Lancet.
[148] T. Nabeshima,et al. Galantamine ameliorates the impairment of recognition memory in mice repeatedly treated with methamphetamine: involvement of allosteric potentiation of nicotinic acetylcholine receptors and dopaminergic-ERK1/2 systems. , 2010, The international journal of neuropsychopharmacology.
[149] Abraham Weizman,et al. Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: A preliminary study , 2008, European Neuropsychopharmacology.
[150] R. Freedman,et al. Genetic linkage to schizophrenia at chromosome 15q14. , 2001, American journal of medical genetics.
[151] Michael A. Dyer,et al. High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia , 2008, Schizophrenia Research.
[152] Daniel R. Weinberger,et al. Neonatal lesions of the rat ventral hippocampus result in hyperlocomotion and deficits in social behaviour in adulthood , 1997, Psychopharmacology.
[153] Nicholas Lange,et al. D-serine added to antipsychotics for the treatment of schizophrenia , 1998, Biological Psychiatry.
[154] C. Vorhees,et al. Effect of (+)-methamphetamine on path integration learning, novel object recognition, and neurotoxicity in rats , 2008, Psychopharmacology.
[155] B. Grayson,et al. Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat , 2007, Behavioural Brain Research.
[156] S. Faraone,et al. Organizational and Visual Memory Deficits in Schizophrenia and Bipolar Psychoses Using the Rey-Osterrieth Complex Figure: Effects of Duration of Illness , 2003, Journal of clinical and experimental neuropsychology.
[157] M. Chan,et al. Attenuation of ketamine-evoked behavioral responses by mGluR5 positive modulators in mice , 2008, Psychopharmacology.
[158] T. Nabeshima,et al. Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors , 2008, Psychopharmacology.
[159] A. Carlsson,et al. Differential effects of the N-methyl-d-aspartate receptor antagonist MK-801 on different stages of object recognition memory in mice , 2007, Neuroscience.
[160] Alexander Easton,et al. Recollection in an episodic-like memory task in the rat. , 2005, Learning & memory.
[161] D. Mathalon,et al. The contribution of constructional accuracy and organizational strategy to nonverbal recall in Schizophrenia and chronic alcoholism , 1992, Biological Psychiatry.
[162] J. A. Dani,et al. Nicotinic Stimulation Produces Multiple Forms of Increased Glutamatergic Synaptic Transmission , 1998, The Journal of Neuroscience.
[163] Yue-Cune Chang,et al. A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia. , 2010, The international journal of neuropsychopharmacology.
[164] 陳柏維,et al. Glycine Transporter I Inhibitor, N-methylglycine (Sarcosine), Added to Clozapine for the Treatment of Schizophrenia , 2005 .
[165] Philip D. Harvey,et al. A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia , 2002, Biological Psychiatry.
[166] J. Coyle,et al. Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis , 2006, Cellular and Molecular Neurobiology.
[167] D. Bowen,et al. NMDA‐induced glutamate and aspartate release from rat cortical pyramidal neurones: evidence for modulation by a 5‐HT1A antagonist , 1995, British journal of pharmacology.
[168] C. Regan,et al. SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models. , 2006, European journal of pharmacology.
[169] T. Bussey,et al. Extensive Cytotoxic Lesions Involving Both the Rhinal Cortices and Area TE Impair Recognition But Spare Spatial Alternation in the Rat , 1997, Brain Research Bulletin.
[170] J. Leon,et al. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors , 2005, Schizophrenia Research.
[171] T. Abel,et al. Deficits in spatial memory correlate with modified γ-aminobutyric acid type A receptor tyrosine phosphorylation in the hippocampus , 2009, Proceedings of the National Academy of Sciences.
[172] B. Pitt. Psychopharmacology , 1968, Mental Health.
[173] P. Mortensen,et al. Obstetric conditions and risk of first admission with schizophrenia: A Danish national register based study , 2007, Schizophrenia Research.
[174] D. Javitt. Sensory processing in schizophrenia: neither simple nor intact. , 2009, Schizophrenia bulletin.
[175] G. Thaker,et al. Nicotine improves delayed recognition in schizophrenic patients , 2004, Psychopharmacology.
[176] Paul W Smith,et al. The discovery of a series of N-substituted 3-(4-piperidinyl)-1,3-benzoxazolinones and oxindoles as highly brain penetrant, selective muscarinic M1 agonists. , 2010, Bioorganic & medicinal chemistry letters.
[177] Sara B. Taylor,et al. Sex-specific neuroendocrine and behavioral phenotypes in hypomorphic Type II Neuregulin 1 rats , 2011, Behavioural Brain Research.
[178] P. Gebicke-haerter,et al. Nicotinamide prevents the long-term effects of perinatal asphyxia on apoptosis, non-spatial working memory and anxiety in rats , 2010, Experimental Brain Research.
[179] J. Waddington,et al. Phenotypic characterization of cognition and social behavior in mice with heterozygous versus homozygous deletion of catechol-O-methyltransferase , 2008, Neuroscience.
[180] A. Lajtha,et al. Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder , 2009, Schizophrenia Research.
[181] Robert C. Smith,et al. Effects of Nicotine Nasal Spray on Cognitive Function in Schizophrenia , 2006, Neuropsychopharmacology.
[182] J. Uslaner,et al. Dose-dependent effect of CDPPB, the mGluR5 positive allosteric modulator, on recognition memory is associated with GluR1 and CREB phosphorylation in the prefrontal cortex and hippocampus , 2009, Neuropharmacology.
[183] S. Mosolov,et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial , 2007, Nature Medicine.
[184] L. Saksida,et al. Muscimol, AP5, or scopolamine infused into perirhinal cortex impairs two-choice visual discrimination learning in rats , 2010, Neurobiology of Learning and Memory.
[185] D. Gaffan,et al. Recognition impaired and association intact in the memory of monkeys after transection of the fornix. , 1974, Journal of comparative and physiological psychology.
[186] M. Carli,et al. WAY 100635, a 5-HT1A receptor antagonist, prevents the impairment of spatial learning caused by intrahippocampal administration of scopolamine or 7-chloro-kynurenic acid , 1997, Brain Research.
[187] S. O'dell,et al. Neurotoxic methamphetamine regimen severely impairs recognition memory in rats , 2003, Synapse.
[188] M. Millan,et al. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], A Preferential Dopamine D3 versus D2 Receptor Antagonist and Potential Antipsychotic Agent: I. Receptor-Binding Profile and Functional Actions at G-Protein-Coupled Receptors , 2008, Journal of Pharmacology and Experimental Therapeutics.
[189] J. Bachevalier,et al. The Hippocampal/Parahippocampal Regions and Recognition Memory: Insights from Visual Paired Comparison versus Object-Delayed Nonmatching in Monkeys , 2004, The Journal of Neuroscience.
[190] John J. Foxe,et al. Impaired visual object recognition and dorsal/ventral stream interaction in schizophrenia. , 2002, Archives of general psychiatry.
[191] Hiroshi Abe,et al. Perirhinal N-methyl-d-aspartate and muscarinic systems participate in object recognition in rats , 2004, Neuroscience Letters.
[192] Young Hoon Kim,et al. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia , 2007, International clinical psychopharmacology.
[193] N. Kanahara,et al. A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia , 2010, Annals of general psychiatry.
[194] G. Higgins,et al. Effect of scopolamine on visual attention in rats , 1995, Psychopharmacology.
[195] Paul J. Harrison,et al. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence , 2005, Molecular Psychiatry.
[196] P. Sullivan,et al. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. , 2003, Archives of general psychiatry.
[197] Jian Fei,et al. Cognitive impairment in mice over-expressing &ggr;-aminobutyric acid transporter I (GAT1) , 2004, Neuroreport.
[198] H. Moore,et al. Trans-Synaptic Stimulation of Cortical Acetylcholine Release after Partial 192 IgG-Saporin-Induced Loss of Cortical Cholinergic Afferents , 1996, The Journal of Neuroscience.
[199] T. Rammsayer,et al. Effects of pharmacologically induced changes in NMDA-receptor activity on long-term memory in humans. , 2001, Learning & memory.
[200] F. Bymaster,et al. Towards a muscarinic hypothesis of schizophrenia , 2007, Molecular Psychiatry.
[201] R. Chesworth,et al. A follow-up study: acute behavioural effects of Δ9-THC in female heterozygous Neuregulin 1 transmembrane domain mutant mice , 2010, Psychopharmacology.
[202] Xuechu Zhen,et al. Evaluation of the antipsychotic effect of bi-acetylated l-stepholidine (l-SPD-A), a novel dopamine and serotonin receptor dual ligand , 2009, Schizophrenia Research.
[203] E. Levin,et al. Nicotine–Haloperidol Interactions and Cognitive Performance in Schizophrenics , 1996, Neuropsychopharmacology.
[204] I. McGregor,et al. Adolescent Rats Find Repeated Δ9-THC Less Aversive Than Adult Rats but Display Greater Residual Cognitive Deficits and Changes in Hippocampal Protein Expression Following Exposure , 2008, Neuropsychopharmacology.
[205] J. N. P. Rawlins,et al. The effects of hippocampal lesions upon spatial and non-spatial tests of working memory , 1986, Behavioural Brain Research.
[206] P. Barberger‐Gateau,et al. The neuroprotective effects of caffeine , 2007, Neurology.
[207] M. Ramírez,et al. Effects of maternal separation on hypothalamic–pituitary–adrenal responses, cognition and vulnerability to stress in adult female rats , 2008, Neuroscience.
[208] J. Feldon,et al. Enhanced recognition memory following glycine transporter 1 deletion in forebrain neurons. , 2007, Behavioral neuroscience.
[209] Mark Weiser,et al. Higher Rates of Cigarette Smoking in Male Adolescents Before the Onset of Schizophrenia: A Historical-Prospective Cohort Study , 2004 .
[210] E. Levin,et al. Acute and Chronic Nicotinic Interactions with Dopamine Systems and Working Memory Performance a , 1995, Annals of the New York Academy of Sciences.
[211] J. Waddington,et al. Sexually dimorphic changes in the exploratory and habituation profiles of heterozygous neuregulin-1 knockout mice , 2006, Neuroreport.
[212] Anne W. Schmidt,et al. Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. , 1997, European journal of pharmacology.
[213] R. Greene. Circuit analysis of NMDAR hypofunction in the hippocampus, in vitro, and psychosis of schizophrenia † , 2001, Hippocampus.
[214] S. Snyder,et al. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. , 1976, Science.
[215] M. Sarter,et al. Trans-synaptic stimulation of cortical acetylcholine and enhancement of attentional functions: a rational approach for the development of cognition enhancers , 1997, Behavioural Brain Research.
[216] G. Griebel,et al. SSR180711, a Novel Selective α7 Nicotinic Receptor Partial Agonist: (1) Binding and Functional Profile , 2007, Neuropsychopharmacology.
[217] Ben Grayson,et al. Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. , 2010, The international journal of neuropsychopharmacology.
[218] John B. Mitchell,et al. The medial frontal cortex and temporal memory: tests using spontaneous exploratory behaviour in the rat , 1998, Behavioural Brain Research.
[219] J. McGinty,et al. Loss of Object Recognition Memory Produced by Extended Access to Methamphetamine Self-Administration is Reversed by Positive Allosteric Modulation of Metabotropic Glutamate Receptor 5 , 2011, Neuropsychopharmacology.
[220] A. Sleight,et al. Impact of regional 5-HT depletion on the cognitive enhancing effects of a typical 5-ht6 receptor antagonist, Ro 04-6790, in the Novel Object Discrimination task , 2008, Psychopharmacology.
[221] R. Clark,et al. Escalating dose, multiple binge methamphetamine regimen does not impair recognition memory in rats , 2007, Synapse.
[222] M. Achaval,et al. Early enriched housing results in partial recovery of memory deficits in female, but not in male, rats after neonatal hypoxia–ischemia , 2008, Brain Research.
[223] P. Celada,et al. In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain , 2007, Psychopharmacology.
[224] M. Morelli,et al. Acute perinatal asphyxia impairs non-spatial memory and alters motor coordination in adult male rats , 2008, Experimental Brain Research.
[225] Robert W. Buchanan,et al. An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia , 2003, Schizophrenia Research.
[226] F. Berna,et al. Functional Mechanisms of Episodic Memory Impairment in Schizophrenia , 2007, Canadian journal of psychiatry. Revue canadienne de psychiatrie.
[227] E. Johnstone,et al. Precursors and prodromata of schizophrenia: findings from the Edinburgh High Risk Study and their literature context , 2006, Psychological Medicine.
[228] I. Grant,et al. Neurocognitive Effects of Methamphetamine: A Critical Review and Meta-analysis , 2007, Neuropsychology Review.
[229] E. Vizi,et al. 5-HT6/7 Receptor Antagonists Facilitate Dopamine Release in the Cochlea via a GABAergic Disinhibitory Mechanism , 2008, Neurochemical Research.
[230] Fang Ji-qian. Haplotype Transmission Disequilibrium Test Based on Haplotype Reconstruction , 2007 .
[231] D. Souza,et al. Caffeine prevents disruption of memory consolidation in the inhibitory avoidance and novel object recognition tasks by scopolamine in adult mice , 2010, Behavioural Brain Research.
[232] M. Quirk,et al. Selective alpha7 nicotinic receptor activation by AZD0328 enhances cortical dopamine release and improves learning and attentional processes. , 2009, Biochemical pharmacology.
[233] M. Hasselmo,et al. NMDA-dependent modulation of CA1 local circuit inhibition , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[234] J. Feldon,et al. Epidemiology-driven neurodevelopmental animal models of schizophrenia , 2010, Progress in Neurobiology.
[235] L. Saksida,et al. Object memory and perception in the medial temporal lobe: an alternative approach , 2005, Current Opinion in Neurobiology.
[236] H. Akil,et al. The 5-HT7 receptor: Role in novel object discrimination and relation to novelty-seeking behavior , 2007, Neuroscience.
[237] D. Weinberger,et al. Postpubertal Emergence of Hyperresponsiveness to Stress and to Amphetamine after Neonatal Excitotoxic Hippocampal Damage: A Potential Animal Model of Schizophrenia , 1993, Neuropsychopharmacology.
[238] A. Simon,et al. Opposing effects of AMPA and 5-HT1A receptor blockade on passive avoidance and object recognition performance: Correlation with AMPA receptor subunit expression in rat hippocampus , 2006, Neuropharmacology.
[239] Peter B. Jones,et al. Substance use in a population-based clinic sample of people with first-episode psychosis , 2007, British Journal of Psychiatry.
[240] C. Robert Cloninger,et al. Further investigation of a chromosome 15 locus in schizophrenia: analysis of affected sibpairs from the NIMH Genetics Initiative. , 1998, American journal of medical genetics.
[241] T. Bussey,et al. Glutamate Receptors in Perirhinal Cortex Mediate Encoding, Retrieval, and Consolidation of Object Recognition Memory , 2005, The Journal of Neuroscience.
[242] P. Pauwels,et al. E-6801, a 5-HT6 receptor agonist, improves recognition memory by combined modulation of cholinergic and glutamatergic neurotransmission in the rat , 2011, Psychopharmacology.
[243] J. Delacour,et al. A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data , 1988, Behavioural Brain Research.
[244] Graham V. Williams,et al. Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory , 2007, Nature Neuroscience.
[245] Carol A. Tamminga,et al. Subanesthetic Doses of Ketamine Stimulate Psychosis in Schizophrenia , 1995, Neuropsychopharmacology.
[246] L. Saksida,et al. Paradoxical Facilitation of Object Recognition Memory after Infusion of Scopolamine into Perirhinal Cortex: Implications for Cholinergic System Function , 2006, The Journal of Neuroscience.
[247] Richie Poulton,et al. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study , 2002, BMJ : British Medical Journal.
[248] B. Pouzet,et al. Beneficial effects of galantamine on performance in the object recognition task in Swiss mice: Deficits induced by scopolamine and by prolonging the retention interval , 2006, Pharmacology Biochemistry and Behavior.
[249] J. Krystal,et al. Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients , 1999, Schizophrenia Research.
[250] N. Schröder,et al. Memantine reduces oxidative damage and enhances long-term recognition memory in aged rats , 2007, Neuroscience.
[251] T. Rubino,et al. Long-lasting recovery of psychotic-like symptoms in isolation-reared rats after chronic but not acute treatment with the cannabinoid antagonist AM251. , 2012, The international journal of neuropsychopharmacology.
[252] S. O'dell,et al. Methamphetamine Influences on Recognition Memory: Comparison of Escalating and Single-Day Dosing Regimens , 2008, Neuropsychopharmacology.
[253] J. Krystal,et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.
[254] J. Gold,et al. Initial phase 2 trial of a nicotinic agonist in schizophrenia. , 2008, The American journal of psychiatry.
[255] L. Squire,et al. The visual paired-comparison task as a measure of declarative memory. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[256] N. Alpert,et al. Impaired recruitment of the hippocampus during conscious recollection in schizophrenia , 1998, Nature Neuroscience.
[257] M. Bös,et al. Influence of the 5-HT6 receptor on acetylcholine release in the cortex: pharmacological characterization of 4-(2-bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl)phenylamine, a potent and selective 5-HT6 receptor antagonist. , 2003, Journal of medicinal chemistry.
[258] J. Neill,et al. Asenapine improves phencyclidine-induced object recognition deficits in the rat: evidence for engagement of a dopamine D1 receptor mechanism , 2011, Psychopharmacology.
[259] K. Mcfarland,et al. AC-260584, an orally bioavailable M1 muscarinic receptor allosteric agonist, improves cognitive performance in an animal model , 2010, Neuropharmacology.
[260] D. Goff,et al. A six-month, placebo-controlled trial of d-cycloserine co-administered with conventional antipsychotics in schizophrenia patients , 2005, Psychopharmacology.
[261] R. Freedman,et al. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia , 1995, Biological Psychiatry.
[262] J. Bachevalier,et al. A comparison of children's performance on two recognition memory tasks: delayed nonmatch-to-sample versus visual paired-comparison. , 1993, Developmental psychobiology.
[263] M. Garcia-Alloza,et al. Lack of localization of 5‐HT6 receptors on cholinergic neurons: implication of multiple neurotransmitter systems in 5‐HT6 receptor‐mediated acetylcholine release , 2006, The European journal of neuroscience.
[264] T. Rubino,et al. Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia. , 2009, The international journal of neuropsychopharmacology.
[265] Young-Chul Chung,et al. Effect of donepezil added to atypical antipsychotics on cognition in patients with schizophrenia: An open-label trial , 2009, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.
[266] N. Pitsikas,et al. The 5-HT1A receptor antagonist WAY 100635 improves rats performance in different models of amnesia evaluated by the object recognition task , 2003, Brain Research.
[267] D. Weinberger,et al. Neonatal Damage of the Ventral Hippocampus Impairs Working Memory in the Rat , 2002, Neuropsychopharmacology.
[268] J. Hagan,et al. Isolation rearing induces recognition memory deficits accompanied by cytoskeletal alterations in rat hippocampus , 2006, The European journal of neuroscience.
[269] P. Seeman,et al. Dopamine D4 receptors elevated in schizophrenia , 1993, Nature.
[270] V. Gallo,et al. cAMP-dependent Protein Kinase Induces cAMP-response Element-binding Protein Phosphorylation via an Intracellular Calcium Release/ERK-dependent Pathway in Striatal Neurons* , 2001, The Journal of Biological Chemistry.
[271] A. de Mendonça,et al. Does caffeine intake protect from Alzheimer's disease? , 2002, European journal of neurology.
[272] M Mishkin,et al. An analysis of short-term visual memory in the monkey. , 1975, Journal of experimental psychology. Animal behavior processes.
[273] K. Hashimoto,et al. Immune Activation During Pregnancy in Mice Leads to Dopaminergic Hyperfunction and Cognitive Impairment in the Offspring: A Neurodevelopmental Animal Model of Schizophrenia , 2006, Biological Psychiatry.
[274] B. Finlay,et al. Translating developmental time across mammalian species , 2001, Neuroscience.
[275] A. Young,et al. PD168077, a D4 receptor agonist, reverses object recognition deficits in rats: potential role for D4 receptor mechanisms in improving cognitive dysfunction in schizophrenia , 2011, Journal of psychopharmacology.
[276] J. Neill,et al. Extrasynaptic GABAA receptor activation reverses recognition memory deficits in an animal model of schizophrenia , 2011, Psychopharmacology.
[277] E X Albuquerque,et al. Properties of neuronal nicotinic acetylcholine receptors: pharmacological characterization and modulation of synaptic function. , 1997, The Journal of pharmacology and experimental therapeutics.
[278] J. Bizot,et al. Intraseptal infusions of a low dose of AP5, a NMDA receptor antagonist, improves memory in an object recognition task in rats , 1998, Neuroscience Letters.
[279] J. Aggleton,et al. Spontaneous object recognition and object location memory in rats: the effects of lesions in the cingulate cortices, the medial prefrontal cortex, the cingulum bundle and the fornix , 1997, Experimental Brain Research.
[280] J. Neill,et al. Positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors reverses sub-chronic PCP-induced deficits in the novel object recognition task in rats , 2010, Behavioural Brain Research.
[281] J. Gardiner. Recognition failures and free-recall failures: Implications for the relation between recall and recognition , 1988, Memory & Cognition.
[282] G. Reynolds,et al. Neonatal lipopolysaccharide induces pathological changes in parvalbumin immunoreactivity in the hippocampus of the rat , 2009, Behavioural Brain Research.
[283] T. Bussey,et al. Removal of cholinergic input to perirhinal cortex disrupts object recognition but not spatial working memory in the rat , 2005, The European journal of neuroscience.
[284] E. Tulving. How many memory systems are there , 1985 .
[285] Michael F. Green,et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. , 2007, Archives of general psychiatry.
[286] W. Riedel,et al. Cholinergic drugs affect novel object recognition in rats: relation with hippocampal EEG? , 2007, European journal of pharmacology.
[287] T. Ehmann,et al. Donepezil in schizophrenia — is it helpful? An experimental design case study , 2001, Acta psychiatrica Scandinavica.
[288] Rosemary A. Cowell,et al. Double Dissociation between the Effects of Peri-Postrhinal Cortex and Hippocampal Lesions on Tests of Object Recognition and Spatial Memory: Heterogeneity of Function within the Temporal Lobe , 2004, The Journal of Neuroscience.
[289] K. Hashimoto,et al. d-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats , 2008, Behavioural Brain Research.
[290] H. Prast,et al. Nitric oxide as modulator of neuronal function , 2001, Progress in Neurobiology.
[291] H. Praag,et al. Caffeine attenuates scopolamine-induced memory impairment in humans , 2005, Psychopharmacology.
[292] A. Sleight,et al. 5-HT6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation—an effect sensitive to NMDA receptor antagonism , 2004, Neuropharmacology.
[293] Lawrence A. Rothblat,et al. Short-term object recognition memory in the rat: nonmatching with trial-unique junk stimuli. , 1987 .
[294] L. W. Cooke,et al. Synthesis and SAR of tolylamine 5-HT6 antagonists. , 2009, Bioorganic & medicinal chemistry letters.
[295] V. Marzo,et al. The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders , 2003 .
[296] Philip D. Harvey,et al. Differential preservation of cognitive functions in geriatric patients with lifelong chronic schizophrenia: less impairment in reading compared with other skill areas , 2000, Biological Psychiatry.
[297] R. Murray,et al. Haplotype transmission disequilibrium and evidence for linkage of the CHRNA7 gene region to schizophrenia in Southern African Bantu families. , 2000, American journal of medical genetics.